Stock Scorecard



Stock Summary for Athira Pharma Inc (ATHA) - $0.30 as of 4/29/2025 7:06:16 AM EST

Total Score

14 out of 30

Safety Score

23 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for ATHA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ATHA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ATHA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ATHA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ATHA (23 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ATHA

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - Athira Pharma ( NASDAQ:ATHA ) 2/27/2025 9:05:00 PM
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND - Athira Pharma ( NASDAQ:ATHA ) 12/6/2024 10:30:00 PM
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND 12/6/2024 10:30:00 PM
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - Athira Pharma ( NASDAQ:ATHA ) 11/7/2024 9:05:00 PM
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Charter Communications ( NASDAQ:CHTR ) 11/1/2024 1:15:00 PM
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease ( CTAD ) 2024 Meeting - Athira Pharma ( NASDAQ:ATHA ) 10/22/2024 11:00:00 AM
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday - Robinhood Markets ( NASDAQ:HOOD ) 9/19/2024 12:29:00 PM
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases 9/17/2024 1:00:00 PM
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More 9/5/2024 3:15:00 PM
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings - Dollar Tree ( NASDAQ:DLTR ) 9/4/2024 5:32:00 PM

Financial Details for ATHA

Company Overview

Ticker ATHA
Company Name Athira Pharma Inc
Country USA
Description Athira Pharma, Inc., a late-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. The company is headquartered in Bothell, Washington.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 12/31/2024
Next Earnings Date 5/13/2025

Stock Price History

Last Day Price 0.30
Price 4 Years Ago 13.03
Last Day Price Updated 4/29/2025 7:06:16 AM EST
Last Day Volume 173,982
Average Daily Volume 188,444
52-Week High 3.67
52-Week Low 0.22
Last Price to 52 Week Low 36.36%

Valuation Measures

Trailing PE N/A
Industry PE 50.76
Sector PE 38.46
5-Year Average PE -2.22
Free Cash Flow Ratio 0.24
Industry Free Cash Flow Ratio 18.72
Sector Free Cash Flow Ratio 41.32
Current Ratio Most Recent Quarter 4.18
Total Cash Per Share 1.24
Book Value Per Share Most Recent Quarter 1.15
Price to Book Ratio 0.25
Industry Price to Book Ratio 10.05
Sector Price to Book Ratio 22.33
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 49.34
Sector Price to Sales Ratio Twelve Trailing Months 25.04
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 39,042,400
Market Capitalization 11,712,720
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 17.62%
Reported EPS 12 Trailing Months -2.52
Reported EPS Past Year 0.00
Reported EPS Prior Year -2.53
Net Income Twelve Trailing Months -96,940,000
Net Income Past Year -96,940,000
Net Income Prior Year -117,672,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 48,438,000
Total Cash Past Year 48,438,000
Total Cash Prior Year 90,584,000
Net Cash Position Most Recent Quarter 48,438,000
Net Cash Position Past Year 48,438,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 1,553,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 44,841,000
Total Stockholder Equity Prior Year 130,188,000
Total Stockholder Equity Most Recent Quarter 44,841,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -97,203,000
Free Cash Flow Per Share Twelve Trailing Months -2.49
Free Cash Flow Past Year -97,203,000
Free Cash Flow Prior Year -101,057,000

Options

Put/Call Ratio 0.05
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.01
MACD Signal -0.02
20-Day Bollinger Lower Band 0.17
20-Day Bollinger Middle Band 0.42
20-Day Bollinger Upper Band 0.66
Beta 3.06
RSI 52.14
50-Day SMA 1.23
150-Day SMA 2.35
200-Day SMA 4.49

System

Modified 4/28/2025 6:01:15 PM EST